Product PortfolioOpevesostat (ODM-208) could sustain growth into the 2030s, with potential peak sales of €1.1 billion and Orion eligible to receive $1.6 billion in milestones.

Sales OutlookNubeqa's peak sales are projected to reach €1.3 billion, backed by Bayer's optimistic outlook, positive doctor feedback, and strong IQVIA script trends.

Bears Say

CompetitionNubeqa faces competition from Xtandi and Erleada, although it is preferred by doctors for better tolerability and flexibility in use with comorbidities.

Orion Corporation News

Is 0M2O a Buy, Before Earnings?

Orion (0M2O) (0M2O) is scheduled to report 2nd quarter earnings on 07/18/2025, before the market opens. Regarding Q2...

23d ago

Orion (0M2O) (0M2O) Q1 Earnings Cheat Sheet

Orion (0M2O) (0M2O) is scheduled to report 1st quarter earnings on 04/23/2025, before the market opens. Regarding Q1...

4M ago

Orion Corporation (0M2O) Announces Q2 Dividend: Read On for Important Dates

Orion Corporation (LSE: 0M2O) has declared, under its dividend policy, a yearly cash dividend in the amount of...

5M ago

0M2O Upcoming Earnings Report: What to Expect?

Orion (0M2O) (0M2O) is scheduled to report 4th quarter earnings on 02/25/2025, before the market opens. Regarding Q4...

6M ago

Orion (0M2O) (0M2O) Q3 Earnings Cheat Sheet

Orion (0M2O) (0M2O) is scheduled to report 3rd quarter earnings on 10/29/2024, before the market opens. Regarding Q3...

9M ago

Is 0M2O a Buy, Before Earnings?

Orion (0M2O) (0M2O) is scheduled to report 4th quarter earnings on 02/13/2024, before the market opens. Regarding Q4...

1y ago

0M2O Upcoming Earnings Report: What to Expect?

Orion (0M2O) (0M2O) is scheduled to report 2nd quarter earnings on 07/17/2023, before the market opens. Regarding Q2...

2y ago

0M2O Upcoming Earnings Report: What to Expect?

Orion (0M2O) (0M2O) is scheduled to report 1st quarter earnings on 04/27/2023, before the market opens. Regarding Q1...

2y ago

0M2O FAQ

What was Orion (0M2O)’s price range in the past 12 months?

Orion (0M2O) lowest share price was €41.43 and its highest was €72.00 in the past 12 months.

What is Orion (0M2O)’s market cap?

Orion (0M2O)’s market cap is €10.02B.

When is Orion (0M2O)’s upcoming earnings report date?

Orion (0M2O)’s upcoming earnings report date is Oct 28, 2025 which is in 81 days.

How were Orion (0M2O)’s earnings last quarter?

Orion (0M2O) released its earnings results on Jul 18, 2025. The company reported €0.59 earnings per share for the quarter, beating the consensus estimate of €0.518 by €0.072.

Is Orion (0M2O) overvalued?

According to Wall Street analysts Orion (0M2O)’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orion (0M2O) pay dividends?

Orion (0M2O) does not currently pay dividends.

What is Orion (0M2O)’s EPS estimate?

Orion (0M2O)’s EPS estimate is 0.65.

How many shares outstanding does Orion (0M2O) have?

Orion (0M2O) has 108,825,490 shares outstanding.

What happened to Orion (0M2O)’s price movement after its last earnings report?

Orion (0M2O) reported an EPS of €0.59 in its last earnings report, beating expectations of €0.518. Following the earnings report the stock price went up 5.035%.

Which hedge fund is a major shareholder of Orion (0M2O)?

Currently, no hedge funds are holding shares in GB:0M2O

Company Description

Orion (0M2O)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.